Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2018-05-11

Clinical Trial Update: U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)

View source ↗

Summary

An observational study evaluating the long-term efficacy of tight control using tocilizumab and/or methotrexate in patients with early rheumatoid arthritis who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • METHOTREXATE (METHOTREXATE)
  • RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED